JP4898666B2 - 抗精神病薬および神経保護薬としてのネボグラミン(neboglamine)(CR2249)の使用 - Google Patents
抗精神病薬および神経保護薬としてのネボグラミン(neboglamine)(CR2249)の使用 Download PDFInfo
- Publication number
- JP4898666B2 JP4898666B2 JP2007513918A JP2007513918A JP4898666B2 JP 4898666 B2 JP4898666 B2 JP 4898666B2 JP 2007513918 A JP2007513918 A JP 2007513918A JP 2007513918 A JP2007513918 A JP 2007513918A JP 4898666 B2 JP4898666 B2 JP 4898666B2
- Authority
- JP
- Japan
- Prior art keywords
- schizophrenia
- nevogramin
- pcp
- treatment
- patent document
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
〔非特許文献2〕Peralta et al., Br. J. Psychiatry 161, 335-343 (1992)
〔非特許文献3〕Sayed et al., Psychopharmacol. Bull. 3J3, 283-288 (1983)
〔非特許文献4〕Garofalo et al. J. Pharm. Pharmacol. 48, 1290-97 (1996)
〔非特許文献5〕Lanza et al., Neuropharmacology 36, 1057-64 (1997)
〔非特許文献6〕Jentsch et al., Neuropsychopharmacology 20,1 201-225 (1999)
〔非特許文献7〕J. Pharmacol. Exp. Ther. 256 530-536 (1991)
〔非特許文献8〕Arch. Int. Pharmadyn. 229, 327-336 (1977)
それ自体では著しい驚愕反応を引き起こさないような弱い刺激が先にあれば、音刺激に対する驚愕反応の程度は減少する。この現象は「プレパルス阻害」(PPI)として知られている。PPI反応は多くの動物および人間にあるが、それとは逆に、統合失調症患者は一般的にPPI欠損を示すとの報告がある。このような欠損はドーパミン作動薬やNMDA拮抗薬のような精神病の症状を誘発する薬剤で、実験的に再現できうる。
この試験は逃げ場のないガラスシリンダー中で泳ぐことを強要して、動物のうつ状態を誘発することからなる。一日あたりPCP 10 mg/kgの (s.c.)注射を14日間、前処理することで、うつ状態は強調された。15日目に、さらに試験30分前に生理溶液またはネボグラミンを前処理した(i.p.)。実験の全継続時間360秒における、数秒間の静止時間(うつの兆候)を評価する。この方法で得られた、実験の3分から6分の間、つまり240秒間に算出された結果は表2に示される。
ネボグラミンと主要代謝産物(CR 2863)が更に神経保護作用活性を示すかについて調査することが決定された。事実、多数の統合失調症患者の亜集団は進行性の脳構造的変性(神経変性)を患っており、認知機能の維持または回復のためその防止が必須であり、かかる特性は非常に有用であることは、明らかである。
Claims (4)
- うつ病の処置用薬剤の製造のための、4,4-ジメチルシクロヘキシルアミン(CR 2863)、またはその医薬的に許容しうる塩の使用。
- 統合失調症の処置用薬剤の製造のための、4,4-ジメチルシクロヘキシルアミン(CR 2863)、またはその医薬的に許容しうる塩の使用。
- 統合失調症の陰性症状の治療処置用薬剤の製造のための、4,4-ジメチルシクロヘキシルアミン(CR 2863)、またはその医薬的に許容しうる塩の使用。
- タイプII双極性障害(躁うつ病)の治療処置用薬剤の製造のための、4,4-ジメチルシクロヘキシルアミン(CR 2863)、またはその医薬的に許容しうる塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000343A ITTO20040343A1 (it) | 2004-05-24 | 2004-05-24 | Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo |
ITTO2004A000343 | 2004-05-24 | ||
PCT/EP2005/052340 WO2005115373A1 (en) | 2004-05-24 | 2005-05-23 | Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008500309A JP2008500309A (ja) | 2008-01-10 |
JP4898666B2 true JP4898666B2 (ja) | 2012-03-21 |
Family
ID=34968609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007513918A Expired - Fee Related JP4898666B2 (ja) | 2004-05-24 | 2005-05-23 | 抗精神病薬および神経保護薬としてのネボグラミン(neboglamine)(CR2249)の使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7737180B2 (ja) |
EP (1) | EP1755583B1 (ja) |
JP (1) | JP4898666B2 (ja) |
AT (1) | ATE464042T1 (ja) |
AU (1) | AU2005247114B2 (ja) |
CA (1) | CA2567397C (ja) |
DE (1) | DE602005020618D1 (ja) |
DK (1) | DK1755583T3 (ja) |
ES (1) | ES2340399T3 (ja) |
IT (1) | ITTO20040343A1 (ja) |
PL (1) | PL1755583T3 (ja) |
PT (1) | PT1755583E (ja) |
WO (1) | WO2005115373A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITTO20050691A1 (it) * | 2005-10-04 | 2007-04-05 | Rottapharm Spa | Uso di neboglamine nella terapia delle tossicodipendenze |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1931927A1 (de) * | 1968-07-06 | 1970-01-15 | Yamanouchi Pharma Co Ltd | Neue Cyclohexylaminderivate |
IT1264765B1 (it) | 1993-03-10 | 1996-10-04 | Rotta Research Lab | Derivati dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso come farmaci potenzianti la |
AR037460A1 (es) | 2001-11-30 | 2004-11-10 | Smithkline Beecham Plc | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion |
-
2004
- 2004-05-24 IT IT000343A patent/ITTO20040343A1/it unknown
-
2005
- 2005-05-23 DK DK05747915.6T patent/DK1755583T3/da active
- 2005-05-23 AU AU2005247114A patent/AU2005247114B2/en not_active Ceased
- 2005-05-23 WO PCT/EP2005/052340 patent/WO2005115373A1/en active Application Filing
- 2005-05-23 JP JP2007513918A patent/JP4898666B2/ja not_active Expired - Fee Related
- 2005-05-23 PL PL05747915T patent/PL1755583T3/pl unknown
- 2005-05-23 ES ES05747915T patent/ES2340399T3/es active Active
- 2005-05-23 CA CA2567397A patent/CA2567397C/en not_active Expired - Fee Related
- 2005-05-23 AT AT05747915T patent/ATE464042T1/de active
- 2005-05-23 EP EP05747915A patent/EP1755583B1/en not_active Not-in-force
- 2005-05-23 DE DE602005020618T patent/DE602005020618D1/de active Active
- 2005-05-23 US US11/569,545 patent/US7737180B2/en not_active Expired - Fee Related
- 2005-05-23 PT PT05747915T patent/PT1755583E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
PL1755583T3 (pl) | 2010-09-30 |
DE602005020618D1 (de) | 2010-05-27 |
WO2005115373A1 (en) | 2005-12-08 |
ITTO20040343A1 (it) | 2004-08-24 |
EP1755583B1 (en) | 2010-04-14 |
AU2005247114A1 (en) | 2005-12-08 |
ATE464042T1 (de) | 2010-04-15 |
PT1755583E (pt) | 2010-05-07 |
AU2005247114B2 (en) | 2010-06-03 |
CA2567397A1 (en) | 2005-12-08 |
US20070249715A1 (en) | 2007-10-25 |
US7737180B2 (en) | 2010-06-15 |
ES2340399T3 (es) | 2010-06-02 |
DK1755583T3 (da) | 2010-07-19 |
EP1755583A1 (en) | 2007-02-28 |
CA2567397C (en) | 2013-03-12 |
JP2008500309A (ja) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bhagya et al. | Short‐term exposure to enriched environment rescues chronic stress‐induced impaired hippocampal synaptic plasticity, anxiety, and memory deficits | |
Xu et al. | Activation of serotonin 2C receptors in dopamine neurons inhibits binge-like eating in mice | |
Zhang et al. | Comparison of ketamine, 7, 8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression | |
Gigliucci et al. | Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism | |
Ren et al. | BDNF–TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms | |
Markus et al. | Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? | |
Elizalde et al. | Sustained stress-induced changes in mice as a model for chronic depression | |
Le Pen et al. | Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol | |
US20230000885A1 (en) | Methods of Treating Psychological and Brain Disorders | |
Rocher et al. | Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants | |
Santiago et al. | Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin | |
Ali et al. | Evidence of the antiepileptic potential of amiloride with neuropharmacological benefits in rodent models of epilepsy and behavior | |
Banjaw et al. | Repeated Catha edulis oral administration enhances the baseline aggressive behavior in isolated rats | |
Yang et al. | Sustained antidepressant action of the N‑methyl‑D‑aspartate receptor antagonist MK‑801 in a chronic unpredictable mild stress model | |
Perry et al. | Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats | |
Peng et al. | Reduced motor cortex GABABR function following chronic alcohol exposure | |
Gammoh et al. | Chlorpheniramine and escitalopram: Similar antidepressant and nitric oxide lowering roles in a mouse model of anxiety | |
Uzbay et al. | Effects of tianeptine on onset time of pentylenetetrazole-induced seizures in mice: possible role of adenosine A1 receptors | |
Ji et al. | Blockade of adenosine A2A receptors reverses early spatial memory defects in the APP/PS1 mouse model of Alzheimer’s disease by promoting synaptic plasticity of adult-born granule cells | |
Nord | Levodopa pharmacokinetics-from stomach to brain: A study on patients with Parkinson’s disease | |
JP4898666B2 (ja) | 抗精神病薬および神経保護薬としてのネボグラミン(neboglamine)(CR2249)の使用 | |
JP2024507492A (ja) | 精神療法を補助するためのメスカリン及びメスカリン類似体(スカリン)の効果 | |
Altunkaynak et al. | Effects of Methylphenidate and Atomoxetine on Development of the Brain | |
JP2009007278A (ja) | 線維筋痛症の治療薬 | |
Yohn | Induction and Treatment of Motivational Dysfunctions in a Rodent Pharmacological Model of Effort-Related Choice Behavior: Evidence from Behavioral and Neurochemical Studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080514 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111025 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111206 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111226 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150106 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |